Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma

Abstract Background Recurrent glioblastoma (rGBM) has limited treatment options. This phase 1 protocol was designed to study the safety and preliminary efficacy of TPI 287, a central nervous system penetrant microtubule stabilizer, in combination with bevacizumab (BEV) for the treatment of rGBM. Met...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Neuro-oncology advances 2024-01, Vol.6 (1), p.vdae009-vdae009
Hauptverfasser:	Goldlust, Samuel A, Nabors, Louis B, Hsu, Sigmund, Mohile, Nimish, Duic, Paul J, Benkers, Tara, Singer, Samuel, Rao, Mayank, Cappello, Lori, Silberman, Sandra L, Farmer, George
Format:	Artikel
Sprache:	eng
Schlagworte:	Clinical Investigations
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!